Fosfomycin intravenous - Zavante Therapeutics

Drug Profile

Fosfomycin intravenous - Zavante Therapeutics

Alternative Names: Fosfomycin disodium; ZOLYD; ZTI-01

Latest Information Update: 05 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Zavante Therapeutics
  • Developer National Institute of Allergy and Infectious Diseases; Zavante Therapeutics
  • Class Antibacterials; Epoxy compounds; Organophosphorus compounds; Phosphonic acids; Phosphoric acid esters; Small molecules
  • Mechanism of Action Cell wall inhibitors; Peptidoglycan inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II/III Urinary tract infections
  • Phase II Intra-abdominal infections; Skin and soft tissue infections
  • Phase I Pseudomonal infections

Most Recent Events

  • 05 Jun 2017 Pharmacokinetics and adverse events data in healthy volunteers presented at the American Society for Microbiology (ASM Microbe-2017)
  • 30 May 2017 Zavante Therapeutics completes the phase-II/III ZEUS clinical trial in Urinary tract infections (In the elderly, In adults) in the US, Belarus, Bulgaria, Croatia, Czech Republic, Estonia, Greece, Georgia, Hungary, Lithuania, Latvia, Poland, Romania, Russia, Slovakia, Ukraine (IV) (NCT02753946)
  • 06 Apr 2017 Efficacy and adverse events data from the phase III ZEUS trial in Urinary tract infections released by Zavante Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top